Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10?? ESWI Influenza Conference 2025
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting
